litigation-funding-analysis-memo.docx

1014-00003 · Optiwave Semiconductor Corp · Pre-Suit Investigation & Strategy

litigation-funding-analysis-memo.docx DOCUMENT Litigation

66 / 83 ← → ✕

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege, the work product doctrine, and all other applicable privileges and protections. It is prepared in anticipation of litigation and for the purpose of providing legal advice to the client. Do not distribute, copy, or disclose this memorandum or its contents to any person or entity without the prior written authorization of Calderwood & Harkness LLP. Inadvertent disclosure does not constitute a waiver of any applicable privilege.

INTERNAL MEMORANDUM

CALDERWOOD & HARKNESS LLP

Date: May 20, 2022

To: Alan Ngo, Responsible Partner, intellectual Property Group, Calderwood & Harkness LLP

From: Marcus Delgado, Billing Partner, intellectual Property Group, Calderwood & Harkness LLP

Re: Litigation Funding Analysis — Review of Resolute Litigation Finance, LP Term Sheet for Partial Funding of Optiwave Semiconductor Corp. v. Lumos Photonics, Inc. Patent Infringement Litigation

Matter Number: 1014-00003

Client: Optiwave Semiconductor Corp.

I. EXECUTIVE SUMMARY

Calderwood & Harkness LLP ("C&H" or the "Firm") was retained by Optiwave Semiconductor Corp. ("OWS" or the "Company") on May 12, 2022, to prosecute a patent infringement action against Lumos Photonics, Inc. ("Lumos") in the United States District Court for the Northern District of California. The proposed action asserts four United States utility patents covering integrated waveguide coupling and photodetector architectures used in high-speed optical transceivers — technologies at the core of Lumos's recently launched product lines. The OWS Board of Directors, including representatives of majority shareholder Vantage Point Capital Partners Fund IV, LP ("Vantage Point"), authorized the litigation on April 28, 2022, with an approved budget of $4.2 million through trial.

Subsequent to our retention, and prior to the filing of the complaint, C&H received an unsolicited term sheet from Resolute Litigation Finance, LP ("Resolute"), a third-party litigation funder headquartered at 399 Park Avenue, 18th Floor, New York, NY 10022. The Resolute term sheet, dated on or about May 10, 2022, proposes to provide $3.0 million in partial funding of the litigation in exchange for a 3.0× return multiple on deployed capital, a 15% residual participation in recoveries above the return threshold, and certain approval and information rights over the conduct of the litigation.

This memorandum has been prepared at your request to provide a comprehensive analysis of the Resolute term sheet. It addresses the following matters: (i) the factual and legal background of the proposed litigation; (ii) the structure and terms of the Resolute funding proposal; (iii) a detailed financial comparison of self-funding versus Resolute-funded litigation economics across multiple recovery scenarios; (iv) an assessment of the control, privilege, confidentiality, and reputational implications of accepting third-party funding; and (v) a recommendation regarding the disposition of the Resolute term sheet.

Recommendation. For the reasons set forth in detail below, I recommend that OWS decline the Resolute Litigation Finance term sheet and proceed with self-funding of the litigation, supported by Vantage Point Capital Partners Fund IV, LP. This recommendation is grounded in the following considerations: (a) the 3.0× return multiple and 15% residual participation represent an extraordinarily high cost of capital that materially dilutes OWS's expected recovery in all positive-outcome scenarios; (b) OWS and Vantage Point have ample financial capacity to self-fund the Board-approved $4.2 million litigation budget, which represents approximately 0.2% of Vantage Point Fund IV's committed capital; (c) Resolute's approval rights over settlement, counsel selection, and significant strategy decisions are inconsistent with OWS's and Vantage Point's strongly expressed desire for unfettered litigation control; (d) the unsettled state of the law regarding privilege protection for communications shared with litigation funders, particularly in the Ninth Circuit, creates unnecessary and potentially outcome-determinative exposure; and (e) the involvement of a third-party funder may signal financial weakness to Lumos and its counsel, undermining OWS's litigation posture.

II. BACKGROUND

A. The Proposed Litigation

OWS is a Delaware corporation headquartered at 2775 Augustine Drive, Suite 400, San Jose, California 95054. The Company is a fabless semiconductor design company specializing in silicon photonics integrated circuits for data center interconnects and telecommunications applications. OWS does not fabricate its own silicon; rather, it designs and develops advanced photonic integrated circuit architectures that are manufactured through foundry partnerships. OWS's products are used by major cloud computing providers and telecommunications equipment manufacturers to enable high-bandwidth, low-latency data transmission across optical networks.

OWS reported fiscal year 2022 revenue of $187.4 million and employs approximately 620 people, the majority of whom are engineers and researchers based at the Company's San Jose headquarters and at a design center in Portland, Oregon. The Company has been profitable on an adjusted EBITDA basis for the past three fiscal years and maintains a strong balance sheet with adequate cash reserves for ongoing operations.

OWS holds a substantial intellectual property portfolio comprising 87 issued United States utility patents and 14 pending patent applications. The portfolio is concentrated in three core technology areas: (i) waveguide coupling architectures for silicon photonics platforms; (ii) germanium-on-silicon photodetectors with enhanced responsivity characteristics; and (iii) modulator driver architectures for high-speed silicon photonic Mach-Zehnder modulators. This portfolio represents the culmination of more than a decade of research and development by OWS's founding team and its engineering organization.

Prior to the commencement of this litigation, OWS engaged Clearpath IP Valuation Services, Inc. to conduct an independent valuation of its patent portfolio. The valuation was led by Jennifer Armitage, CFA, CLP, a recognized expert in intellectual property valuation with particular experience in the semiconductor and photonics sectors. Clearpath's analysis concluded that the OWS patent portfolio has a portfolio-level fair market value of approximately $215 million. Of particular relevance to this memorandum, Clearpath valued the four patents proposed for assertion in this litigation at a combined value of approximately $42.8 million, reflecting their centrality to the silicon photonics transceiver market and their strength as enforcement assets.

The defendant, Lumos Photonics, Inc. ("Lumos"), is a Delaware corporation headquartered at 9400 McNeil Drive, Building 7, Austin, Texas 78758. Lumos is a publicly traded company listed on the Nasdaq Stock Market under the ticker symbol "LMPH." For fiscal year 2022, Lumos reported revenue of approximately $312.8 million and employs approximately 1,450 people. As of the anticipated filing date, Lumos's market capitalization is approximately $1.87 billion. Lumos designs, manufactures, and markets optical transceiver modules and optical engine sub-assemblies for data center and telecommunications applications. The largest institutional shareholder of Lumos is Ridgeline Asset Management, LLC, which holds an approximate 9.2% equity stake.

The accused products in this action are: (i) the LumosBridge™ 800G Optical Engine, which carries a unit price in the range of $1,200 to $1,800 and was first shipped to customers in the first quarter of 2022; and (ii) the LumosEdge™ 400ZR+ Pluggable Transceiver, which carries a unit price in the range of $600 to $900 and has been in commercial production since the third quarter of 2021. Based on OWS's market intelligence and publicly available financial data, the combined accused product revenue for calendar year 2022 is estimated at approximately $148.6 million. The pre-suit damages period — spanning the first and second quarters of 2022 — accounts for approximately $62.3 million of that total.

OWS's technical team, working with outside technical consultants, has conducted a detailed claim-by-claim mapping of the accused Lumos products against the asserted patent claims. That analysis, which was presented to the Board as part of the April 28, 2022 litigation authorization meeting, concludes that both accused products practice multiple claims of each of the four asserted patents. The infringement analysis is supported by publicly available product datasheets, Lumos's published technical papers and conference presentations, teardown analyses of purchased Lumos products, and reverse engineering of the optical and electronic subsystems.

B. The Patents-in-Suit

The four United States utility patents proposed for assertion in this action are summarized below:

U.S. Patent No. 10,234,567 (the "'567 Patent"). Entitled "Integrated Waveguide Coupler with Tapered Mode Converter for Silicon Photonics Platforms," the '567 Patent was filed on March 14, 2017, and issued on March 19, 2019. The named inventors are Dr. Kevin Fong, Dr. Priya Ramanathan, and Hideo Tanaka. The '567 Patent is directed to a novel waveguide coupler architecture that utilizes a tapered mode converter to achieve low-loss optical coupling between an external optical fiber and a silicon photonic waveguide. The claimed invention addresses a long-standing challenge in silicon photonics — the significant mode-field mismatch between standard single-mode optical fibers and sub-micron silicon waveguides. The '567 Patent contains 24 claims, including 4 independent claims.

U.S. Patent No. 10,891,234 (the "'234 Patent"). Entitled "Germanium-on-Silicon Photodetector with Graded Buffer Layer for Enhanced Responsivity," the '234 Patent was filed on September 8, 2017, and issued on January 14, 2021. The named inventors are Dr. Kevin Fong and Dr. Amara Osei. The '234 Patent discloses and claims a germanium-on-silicon photodetector structure that employs a graded silicon-germanium buffer layer to reduce threading dislocation density at the germanium-silicon interface, thereby enhancing photodetector responsivity and reducing dark current. The '234 Patent contains 18 claims, including 3 independent claims.

U.S. Patent No. 11,045,678 (the "'678 Patent"). Entitled "Multi-Channel Optical Transceiver with Integrated Wavelength-Division Multiplexing on Silicon," the '678 Patent was filed on June 22, 2018, and issued on June 29, 2021. The named inventors are Dr. Priya Ramanathan, Dr. Amara Osei, and Liwei Zhang. The '678 Patent is directed to a multi-channel transceiver architecture that integrates wavelength-division multiplexing (WDM) functionality directly onto a silicon photonic chip, eliminating the need for discrete external multiplexing components and enabling higher-density optical interconnects. The '678 Patent contains 22 claims, including 3 independent claims.

U.S. Patent No. 11,312,890 (the "'890 Patent"). Entitled "Driver Circuit Architecture for High-Speed Silicon Photonic Mach-Zehnder Modulators," the '890 Patent was filed on November 15, 2018, and issued on April 26, 2022. The named inventors are Dr. Kevin Fong and Rajesh Iyer. The '890 Patent claims a novel driver circuit architecture optimized for high-speed Mach-Zehnder modulator structures in silicon photonics, addressing signal integrity and power consumption challenges at data rates of 100 Gbps per lane and above. The '890 Patent contains 20 claims, including 4 independent claims. Notably, the '890 Patent issued less than one month prior to the date of this memorandum, and its claims were allowed without any rejections on prior art grounds during prosecution.

All four patents are currently assigned to OWS and are in force. Maintenance fees are current. No inter partes review, post-grant review, or ex parte reexamination proceedings have been initiated against any of the four patents as of the date of this memorandum, although we anticipate that Lumos will likely petition for inter partes review of one or more of these patents following the filing of the complaint.

C. Projected Damages and Litigation Economics

Based on our preliminary analysis of the damages landscape, OWS's claimed damages are believed to exceed $75 million. This estimate is grounded in a reasonable royalty theory of damages under 35 U.S.C. § 284, applying the Georgia-Pacific factor framework. Specifically, the damages analysis contemplates an estimated royalty rate of 7.5% applied to the accused product revenue base. Applying this rate to the estimated calendar year 2022 accused product revenue of $148.6 million yields a base annual royalty of approximately $11.145 million. The total claim value is enhanced by: (i) the pre-suit damages period, during which Lumos was on notice of OWS's patent rights by virtue of the cease-and-desist letter sent on March 15, 2022; (ii) post-suit damages accruing through the anticipated trial date; and (iii) the potential for willfulness enhancement of up to three times the damages found, pursuant to 35 U.S.C. § 284, given Lumos's apparent knowledge of OWS's patent portfolio and the absence of any opinion of counsel or design-around effort.

The Board-approved litigation budget of $4.2 million encompasses all anticipated attorneys' fees, expert costs, and litigation disbursements through trial. This budget was developed by C&H in consultation with OWS's General Counsel, Margaret Liu, and was presented to and approved by the Board at its April 28, 2022 meeting.

The fee arrangement between OWS and Calderwood & Harkness provides for a blended hourly rate with a 10% volume discount on the Firm's standard rates. OWS maintains a $100,000 evergreen retainer that is replenished on a quarterly basis. The applicable standard billing rates and effective rates (after the 10% discount) for the core litigation team are as follows:

In addition to attorneys' fees, the litigation budget includes estimated expert costs of $400,000 to $500,000 through trial. The Firm has identified and engaged, subject to OWS's approval, two experts for this matter: (i) Dr. Harold Whitfield of Whitfield Technical Consulting Group, Inc., who will serve as OWS's technical expert on infringement, validity, and claim construction; and (ii) Dr. Lawrence Kessler of Apex Claim Analytics LLC, who will serve as OWS's damages expert. Both experts are experienced in patent litigation in the semiconductor and photonics fields and have testified in prior proceedings before the Northern District of California and the International Trade Commission.

D. OWS Ownership and Capital Structure

OWS is majority-owned by Vantage Point Capital Partners Fund IV, LP ("Vantage Point" or "Fund IV"), which holds approximately 62% of the Company's fully diluted equity. The general partner of Fund IV is Vantage Point Capital GP IV, LLC, headquartered at 2600 Sand Hill Road, Suite 200, Menlo Park, California 94025. Vantage Point Fund IV is a $2.1 billion private equity fund with a 2018 vintage year. The fund's managing partner is Douglas Fairbanks III, and the operating partner responsible for the semiconductor sector is Rebecca Torres.

Vantage Point's total equity investment in OWS, across Series C and Series D preferred stock rounds, is approximately $74.5 million. Vantage Point holds three of the seven seats on the OWS Board of Directors, giving it significant but not unilateral control over major corporate decisions. The remaining equity in OWS is held by the Company's founders — Dr. Priya Ramanathan and Dr. Kevin Fong — along with members of the management team and certain angel investors who participated in the Company's earlier financing rounds.

OWS's primary lending relationship is with First Pacific Commerce Bank, N.A. ("FPCB"), located at 345 Montgomery Street, San Francisco, California 94104. OWS maintains a $40 million revolving credit facility with FPCB, secured by a blanket lien on the Company's intellectual property assets. While the credit facility provides additional liquidity, drawing on it for the purpose of funding litigation expenses may raise issues under the financial covenants governing the facility, and any such draw would require separate analysis and potentially the consent of FPCB. For the purposes of this memorandum, the analysis of OWS's capacity to self-fund the litigation does not assume any draw on the FPCB credit facility.

The capital structure and financial position of OWS and Vantage Point are directly relevant to the analysis of whether third-party litigation funding is necessary or advisable. As discussed in greater detail in Section V.B below, the Board-approved litigation budget of $4.2 million is well within OWS's operational capacity and represents an immaterial amount relative to Vantage Point Fund IV's committed capital.

III. RESOLUTE LITIGATION FINANCE, LP — OVERVIEW

Resolute Litigation Finance, LP ("Resolute") is a Delaware limited partnership headquartered at 399 Park Avenue, 18th Floor, New York, New York 10022. Resolute is a third-party litigation funder that specializes in providing non-recourse financing for commercial litigation and intellectual property enforcement actions. Based on publicly available information and our own review, Resolute manages several hundred million dollars in committed capital across multiple fund vehicles and has funded patent infringement cases, antitrust claims, and complex commercial disputes.

Resolute approached OWS and Calderwood & Harkness with an unsolicited expression of interest in funding the contemplated patent infringement action against Lumos. Based on our understanding, Resolute became aware of the potential litigation through market intelligence sources; specifically, several silicon photonics trade publications reported in late March and early April 2022 that OWS had sent a cease-and-desist letter to Lumos on March 15, 2022, alleging infringement of multiple patents related to waveguide coupling and photodetector technologies. It is not uncommon for litigation funders to monitor trade press, patent assignment databases, and litigation dockets for opportunities, and Resolute's outreach is consistent with that practice.

The Resolute term sheet was received by Calderwood & Harkness on or about May 10, 2022 — two days before C&H was formally retained by OWS to prosecute the action. The timing of the term sheet, while coincidental, does not appear to reflect any improper access to privileged information. Nonetheless, the fact that Resolute was able to identify and pursue this opportunity so quickly underscores the transparency of the marketplace and the extent to which OWS's enforcement activities may already be visible to market participants, including Lumos and its advisors.

We have reviewed publicly available information regarding Resolute's track record, management team, and standard deal terms. While Resolute has funded a number of successful patent enforcement campaigns, the terms proposed in this instance — particularly the 3.0× return multiple and the breadth of the approval rights — are at the higher end of the range we have observed in the third-party litigation funding market for patent infringement cases with the profile of this action. This observation informs the financial analysis set forth in Section V below.

IV. SUMMARY OF RESOLUTE TERM SHEET — KEY TERMS

The following is a summary of the material terms of the Resolute term sheet. This summary is not intended to be exhaustive and is qualified in its entirety by the term sheet itself, which is enclosed as Attachment A. We note that the term sheet is a non-binding indication of Resolute's proposed terms and would be subject to further negotiation and the execution of a definitive funding agreement.

A. Funding Amount and Structure

Resolute proposes to commit $3.0 million to fund a portion of the litigation costs, including attorneys' fees, expert costs, and litigation disbursements. This amount represents approximately 71% of the Board-approved litigation budget of $4.2 million. OWS would remain responsible for funding the balance of litigation costs in excess of $3.0 million, which, based on the current budget, is estimated at approximately $1.2 million.

The proposed funding would be disbursed in four equal tranches of $750,000 each, tied to the achievement of specified litigation milestones:

(i) Tranche 1 — $750,000: Payable upon execution of the definitive funding agreement and the filing of the complaint;

(ii) Tranche 2 — $750,000: Payable upon completion of claim construction briefing (i.e., the filing of all Markman hearing briefs and supporting materials);

(iii) Tranche 3 — $750,000: Payable upon completion of fact discovery (including the close of all fact depositions and the expiration of the fact discovery deadline set by the court);

(iv) Tranche 4 — $750,000: Payable upon the commencement of trial (i.e., the first day of jury selection or, in a bench trial, the first day of the presentation of evidence).

Funds disbursed by Resolute would be applied first to C&H invoices for fees and costs, and thereafter to expert fees and other litigation disbursements. This sequencing is significant because it means that Resolute's capital would effectively subsidize C&H's fees first, with expert costs funded out of the remaining balance or by OWS directly. Depending on the pace of fee accrual relative to the milestone schedule, there could be periods during the litigation when OWS is required to fund C&H fees and expert costs from its own resources while awaiting the next tranche disbursement.

B. Return Multiple and Waterfall

The economic terms of the Resolute proposal are structured around a return multiple and a residual participation mechanism. Specifically:

Return Multiple. Resolute is entitled to a return of 3.0× on its total deployed capital from any litigation proceeds. If Resolute deploys the full $3.0 million commitment, its first-dollar return entitlement would be $9.0 million. This return is calculated on deployed (i.e., actually disbursed) capital, not on the total commitment. If the litigation settles or concludes before all four tranches are disbursed, the return multiple applies only to the capital that has been drawn.

Residual Participation. If the total recovery from the litigation — whether by way of settlement, judgment, or otherwise — exceeds $9.0 million, Resolute is entitled to an additional 15% of the amount by which the total recovery exceeds $9.0 million. This residual participation is uncapped and would apply to any incremental recovery regardless of its magnitude.

The waterfall governing the distribution of any settlement or judgment proceeds is as follows:

(1) First: Reimbursement of OWS's self-funded litigation costs (estimated at $1.2 million based on the current budget);

(2) Second: Payment of Resolute's 3.0× return on deployed capital ($9.0 million on full deployment);

(3) Third: Payment of 15% of the remaining proceeds (above $9.0 million) to Resolute; and

(4) Fourth: Payment of the balance to OWS.

In the event of a walk-away or zero-recovery scenario — whether resulting from an adverse judgment, a voluntary dismissal, or otherwise — Resolute bears its funded amount as a loss. The funding is non-recourse to OWS, meaning that OWS has no obligation to repay any portion of Resolute's deployed capital in a zero-recovery outcome. This non-recourse feature is the principal economic benefit of litigation funding and represents the risk that Resolute assumes in exchange for the return multiple and residual participation described above.

C. Control and Approval Rights

The Resolute term sheet includes a set of approval and control rights that would grant Resolute significant influence over the conduct of the litigation. The specific approval rights are as follows:

(i) Selection and Replacement of Lead Counsel. Resolute retains approval rights over the selection and replacement of lead litigation counsel. While OWS's current selection of Calderwood & Harkness would presumably be approved as part of the initial funding agreement, any subsequent change in lead counsel — whether initiated by OWS or necessitated by circumstances — would require Resolute's consent.

(ii) Settlement Approval. Resolute retains approval rights over the settlement of claims for less than $15 million. This means that if OWS and C&H determine that a settlement at or below $15 million is in OWS's best interests — for example, following an adverse claim construction ruling or other litigation development — OWS could not accept such a settlement without Resolute's consent.

(iii) Voluntary Dismissal or Abandonment. Resolute retains approval rights over any voluntary dismissal or abandonment of claims, whether in whole or in part.

(iv) Significant Litigation Strategy Decisions. Resolute retains approval rights over significant litigation strategy decisions, including but not limited to venue transfer motions and claim narrowing decisions. The term sheet does not define "significant litigation strategy decisions" with precision, creating ambiguity about the scope of Resolute's approval authority.

Notwithstanding these approval rights, the term sheet provides that OWS retains day-to-day litigation management through its chosen counsel, Calderwood & Harkness. This distinction between "day-to-day management" and "significant strategy decisions" is, however, inherently imprecise and is likely to give rise to disputes during the course of the litigation.

In addition to the approval rights, Resolute is entitled to quarterly litigation status reports prepared by C&H, copies of all significant filings (including motions, briefs, and court orders), and access to C&H attorneys for strategy briefings. Resolute also has the right to attend, as an observer, any mediation or settlement conference. These information and observation rights, while less intrusive than the approval rights, create additional administrative burden and raise privilege and confidentiality concerns discussed in Section V.D below.

D. Information Rights and Confidentiality

The Resolute term sheet provides Resolute with broad information rights, including the right to review all non-privileged litigation materials, expert reports, and key discovery documents. These information rights are intended to enable Resolute to monitor the progress of the litigation and to make informed decisions regarding the exercise of its approval rights.

A critical issue raised by these information rights is the question of whether sharing privileged materials — including attorney-client communications and attorney work product — with Resolute would constitute a waiver of the attorney-client privilege or work product protection. The term sheet contemplates that certain privileged communications may be shared with Resolute under the common interest doctrine, which permits the sharing of privileged information among parties with a common legal interest without waiving the privilege. However, the application of the common interest doctrine to communications between a litigant and its litigation funder is not settled law in all jurisdictions, and the question has not been definitively resolved by the Ninth Circuit Court of Appeals — the circuit encompassing the Northern District of California, which is the anticipated venue for this action. This issue is analyzed in greater detail in Section V.D below.

The term sheet also requires Resolute to be bound by confidentiality provisions and to execute a confidentiality agreement that is compatible with any court-entered protective order. While this is a standard provision in litigation funding arrangements, its effectiveness depends in part on whether the court's protective order specifically contemplates and permits the disclosure of information to litigation funders, which cannot be assumed.

E. Term and Termination

The funding agreement contemplated by the term sheet would terminate upon the final resolution of the litigation, whether by judgment, settlement, or voluntary dismissal. The term sheet also addresses the circumstances under which each party may terminate the arrangement prior to final resolution:

Resolute's Termination Rights. Resolute may terminate the funding arrangement if: (i) OWS materially breaches the funding agreement; (ii) a court enters a final, non-appealable adverse judgment in the litigation; or (iii) OWS refuses to follow reasonable litigation strategy recommendations made by Resolute. The inclusion of item (iii) is notable because it effectively gives Resolute a termination right triggered by a disagreement over litigation strategy, which could be exercised in situations where OWS and C&H believe that a particular strategic approach is in OWS's best interest but Resolute disagrees.

Upon termination by Resolute, Resolute forfeits its deployed capital — consistent with the non-recourse nature of the funding — but OWS becomes immediately responsible for all future litigation costs without the benefit of any further Resolute funding.

OWS's Termination Rights. OWS may terminate the funding arrangement at any time, but only upon repayment of Resolute's deployed capital plus a 1.5× return. This buyout provision means that if OWS wishes to extricate itself from the funding arrangement after Resolute has deployed the full $3.0 million, OWS would be required to pay Resolute $4.5 million. This buyout cost is in addition to the litigation costs that OWS would continue to bear going forward.

The asymmetry of the termination provisions is noteworthy. Resolute can walk away with no further obligation if it loses confidence in the litigation, while OWS can exit the arrangement only by paying a premium over deployed capital. This structure is common in third-party litigation funding but is nonetheless unfavorable to the funded party.

V. ANALYSIS: SELF-FUNDING VS. RESOLUTE FUNDING

A. Financial Comparison

The core question presented by the Resolute term sheet is whether the economics of third-party funding justify the cost, given OWS's capacity to self-fund the litigation. To address this question, I have modeled four recovery scenarios that span the range of reasonably probable outcomes. The detailed scenario analysis is presented in Attachment B; the key results are summarized below.

1. Scenario 1: Successful Outcome — $75 Million Recovery

This scenario assumes that OWS achieves its targeted recovery of $75 million, whether through a favorable judgment or a settlement at or near the claimed damages amount.

Self-Funded. Under a self-funded approach, OWS bears the full $4.2 million litigation budget and retains the entirety of the $75 million recovery. Net to OWS: approximately $70.8 million.

Resolute-Funded. Under the Resolute term sheet, proceeds would be distributed as follows:

• OWS reimbursement of self-funded costs: $1.2 million

• Resolute 3.0× return: $9.0 million (3.0 × $3.0 million deployed)

• Resolute 15% residual: 15% × ($75.0M − $9.0M − $1.2M) = 15% × $64.8M = $9.72 million

• Total Resolute take: $18.72 million

• Net to OWS: $75.0M − $4.2M (total litigation costs) − $18.72M (Resolute take) = $52.08 million

Cost of Resolute Funding. In this scenario, the cost of Resolute funding to OWS is $18.72 million. This represents a 24.96% effective tax on the gross recovery, or, stated differently, a 624% effective return to Resolute on its $3.0 million deployed capital. OWS's net recovery is reduced by approximately $18.72 million — a sum that far exceeds the $3.0 million in risk capital provided by Resolute and that would otherwise flow entirely to OWS and its shareholders.

2. Scenario 2: Moderate Settlement — $25 Million Recovery

This scenario assumes a moderate settlement of $25 million, which might result from a partially favorable claim construction ruling or other litigation developments that narrow the case but do not eliminate OWS's leverage.

Self-Funded. OWS bears the full $4.2 million budget. Net to OWS: $25.0M − $4.2M = $20.8 million.

Resolute-Funded. Distribution of proceeds:

• OWS reimbursement of self-funded costs: $1.2 million

• Resolute 3.0× return: $9.0 million

• Resolute 15% residual: 15% × ($25.0M − $9.0M − $1.2M) = 15% × $14.8M = $2.22 million

• Total Resolute take: $11.22 million

• Net to OWS: $25.0M − $4.2M − $11.22M = $9.58 million

Cost of Resolute Funding. The cost of Resolute funding in this scenario is $11.22 million, representing a 44.88% effective tax on gross recovery. OWS's net recovery is reduced from $20.8 million (self-funded) to $9.58 million (Resolute-funded) — a reduction of more than 53%. At a $25 million recovery level, Resolute captures more of the litigation proceeds than OWS itself.

3. Scenario 3: Small Settlement — $10 Million Recovery

This scenario assumes a small settlement of $10 million, which might result from an unfavorable claim construction ruling, an adverse inter partes review outcome, or other developments that significantly weaken OWS's case.

Self-Funded. OWS bears the full $4.2 million budget. Net to OWS: $10.0M − $4.2M = $5.8 million.

Resolute-Funded. Distribution of proceeds:

• OWS reimbursement of self-funded costs: $1.2 million

• Resolute 3.0× return: $9.0 million

• Resolute 15% residual: 15% × ($10.0M − $9.0M − $1.2M) = 15% × (−$0.2M) = $0 (the calculation yields a negative number, so no additional residual participation is payable)

• Total Resolute take: $9.0 million

• Net to OWS: $10.0M − $4.2M (total litigation costs, of which $1.2M is self-funded) − $9.0M (Resolute take) = −$3.2 million on a gross basis

In practical terms, OWS would not owe Resolute more than the litigation proceeds allow. However, after application of the waterfall, OWS's $1.2 million in self-funded costs is reimbursed first, Resolute's $9.0 million entitlement is then satisfied from the remaining $8.8 million of proceeds (leaving a $200,000 shortfall in Resolute's return, which would be absorbed by Resolute under the non-recourse structure), and nothing remains for OWS. OWS's effective net position is approximately zero (retaining only the $1.2 million reimbursement offset against the $1.2 million already spent), while also having incurred $4.2 million in total litigation costs.

Cost of Resolute Funding. This scenario starkly illustrates the punitive effect of the 3.0× return multiple on lower-value outcomes. Resolute's return structure consumes virtually the entirety of the recovery, leaving OWS with no net benefit from the litigation despite a $10 million settlement.

4. Scenario 4: Zero Recovery (Walk-Away or Adverse Judgment)

This scenario assumes that the litigation results in no recovery to OWS — whether because of a final adverse judgment, a voluntary dismissal, or an unfavorable resolution of invalidity or non-infringement challenges.

Self-Funded. OWS absorbs the full $4.2 million in litigation costs as a total loss.

Resolute-Funded. Resolute absorbs its $3.0 million in deployed capital as a loss, consistent with the non-recourse structure. OWS absorbs only its $1.2 million self-funded portion. OWS's total loss is $1.2 million rather than $4.2 million.

OWS Savings. In this scenario, OWS saves $3.0 million by virtue of the non-recourse funding. This is the only scenario in which Resolute funding provides a net economic benefit to OWS. However, it is also, by definition, the least desirable litigation outcome — one in which OWS's patent rights are not vindicated and no monetary recovery is obtained.

The following summary table compiles the results of the four scenarios:

The financial analysis demonstrates that Resolute funding is favorable to OWS only in the zero-recovery scenario, where it functions as a form of insurance against total loss. In every scenario involving a positive recovery, the cost of Resolute funding is substantial and disproportionate to the capital provided. In the most likely successful outcome (Scenario 1), Resolute's $18.72 million take represents more than six times its deployed capital. In the moderate settlement scenario, Resolute captures more value than OWS. And in the small settlement scenario, Resolute's return structure effectively eliminates OWS's net recovery entirely.

B. OWS/Vantage Point Capacity to Self-Fund

The financial analysis set forth above would counsel against Resolute funding even if OWS lacked the resources to self-fund the litigation. However, the case against Resolute funding is further strengthened by the fact that OWS and its principal shareholder, Vantage Point Capital Partners Fund IV, LP, have ample capacity to self-fund the Board-approved litigation budget of $4.2 million.

OWS itself generates annual revenue of $187.4 million, operates at positive cash flow, and is operationally solvent. While the Company maintains a $40 million revolving credit facility with First Pacific Commerce Bank, N.A., which could provide an additional source of liquidity if needed, drawing on the credit facility for litigation expenses may raise covenant compliance issues under the credit agreement and is not contemplated or recommended at this time. The $4.2 million litigation budget represents approximately 2.2% of OWS's annual revenue — a meaningful but manageable expenditure for a company of OWS's size and financial profile.

More significantly, OWS's majority shareholder, Vantage Point Capital Partners Fund IV, LP, has $2.1 billion in committed capital. The $4.2 million litigation budget represents approximately 0.2% of the fund's total committed capital — an amount that is, by any measure, immaterial to Vantage Point. Vantage Point has invested $74.5 million in OWS and has a direct financial interest in maximizing the value of OWS's intellectual property portfolio. The successful prosecution of this patent infringement action would protect and enhance the value of that investment.

We have confirmed through conversations with OWS's General Counsel, Margaret Liu, that Vantage Point's Operating Partner, Rebecca Torres, and Managing Partner, Douglas Fairbanks III, have indicated their willingness to support the litigation budget through OWS's existing capital resources. The Board's April 28, 2022 authorization of the $4.2 million budget was made with the full support of the Vantage Point board representatives, and there is no indication that OWS faces any constraint on its ability to fund the litigation from internal resources.

In sum, the economic rationale for third-party litigation funding — namely, to provide capital that the litigant cannot otherwise access — is simply not present here. OWS has the means to self-fund, and the cost of external capital from Resolute is grossly disproportionate to the benefit received.

C. Control Considerations

Beyond the financial analysis, the control provisions of the Resolute term sheet raise significant strategic and practical concerns that independently counsel against acceptance of the term sheet.

Settlement Approval Rights. Resolute's veto right over settlements below $15 million creates a particularly dangerous strategic constraint. Patent infringement litigation is inherently uncertain, and the outcome of any individual case can be significantly affected by developments that are difficult to predict at the outset — including claim construction rulings, inter partes review outcomes, summary judgment motions, and changes in the technology market. If any of these developments materially weakens OWS's case, a rational litigant might conclude that a settlement in the range of $5 million to $15 million represents a favorable outcome relative to the risk-adjusted expected value of continuing to trial. Under the Resolute term sheet, OWS could not accept such a settlement without Resolute's consent. Resolute's interests in this situation would diverge from OWS's: because Resolute's non-recourse structure means that it loses its deployed capital in a zero-recovery outcome, Resolute has an incentive to continue litigating even when the risk-adjusted expected value of doing so is negative for OWS, because the downside to Resolute is capped at its deployed capital while the upside includes its 3.0× return multiple and 15% residual participation.

Counsel Selection and Replacement. Resolute's approval right over the selection and replacement of lead counsel is unusual in scope and potentially intrusive to the attorney-client relationship. The engagement between OWS and Calderwood & Harkness was negotiated directly between the Company and the Firm, based on OWS's and Vantage Point's confidence in C&H's intellectual property litigation capabilities. Any funder interference with this relationship — whether through the initial approval process or through a subsequent disagreement about counsel performance — would undermine the trust and independence that are essential to effective legal representation. Moreover, the approval right creates the risk that Resolute could use its counsel-selection authority as leverage in disputes over settlement or strategy.

Significant Strategy Decisions. The term sheet's requirement that Resolute approve "significant litigation strategy decisions" — including venue transfer motions and claim narrowing — is both broad and imprecise. It is unclear from the term sheet what constitutes a "significant" decision as opposed to a "day-to-day" management decision. This ambiguity is likely to generate friction as the litigation progresses and could delay time-sensitive tactical decisions while approval from Resolute is sought.

OWS and Vantage Point Preference. Both OWS management and the Vantage Point board representatives have expressed a strong preference for retaining full and unfettered control over the prosecution of this litigation. The Board's authorization of the litigation on April 28, 2022 was predicated on the assumption that OWS and its chosen counsel would have complete autonomy to make all strategic and tactical decisions, including settlement decisions. The introduction of a third-party funder with approval rights over these decisions is fundamentally inconsistent with that expectation.

D. Privilege and Confidentiality Risks

The sharing of litigation strategy materials, attorney-client communications, and attorney work product with a litigation funder such as Resolute raises significant and, in the relevant jurisdiction, unresolved privilege concerns.

The attorney-client privilege protects confidential communications between a client and its attorney made for the purpose of obtaining or providing legal advice. The work product doctrine protects materials prepared by or for an attorney in anticipation of litigation. Both protections can be waived by voluntary disclosure of the protected material to a third party who does not share a common legal interest with the disclosing party.

The common interest doctrine (sometimes referred to as the "joint defense privilege" or "allied litigant doctrine") is an exception to the general waiver rule. It permits the sharing of privileged communications among parties who share a common legal interest without constituting a waiver of the privilege. Some courts have applied the common interest doctrine to communications between litigants and their litigation funders, on the theory that the funder and the funded party share a common interest in the successful outcome of the litigation.

However, the application of the common interest doctrine to litigation funding relationships is far from settled. Courts in different jurisdictions have reached conflicting conclusions, and the Ninth Circuit — which encompasses the Northern District of California, the anticipated venue for this action — has not definitively resolved the question. In the absence of clear Ninth Circuit authority, there is a meaningful risk that a court could conclude that the common interest doctrine does not apply to the Resolute funding relationship, and that the disclosure of privileged materials to Resolute constitutes a waiver of the privilege as to those materials.

If privilege were deemed waived as to communications shared with Resolute, the consequences could be severe. Lumos's counsel — Brannick Howell & Stein LLP, led by partner Victoria Ashworth, who is known in the patent litigation community for her aggressive and thorough litigation tactics — would likely seek discover the existence and terms of the funding arrangement, as well as any privileged communications that were shared with Resolute. Discovery of the funding arrangement could provide Lumos with valuable insights into OWS's litigation strategy, settlement parameters, and risk assessment. It could also be used to argue that OWS's litigation decisions are being driven by the funder's financial interests rather than by a good-faith belief in the merits of its patent claims.

Additionally, the protective order that the parties would negotiate and submit to the court at the outset of the litigation would not necessarily shield funder communications from discovery. Protective orders typically govern the handling of discovery materials produced by the parties; they do not create an independent basis for shielding otherwise discoverable information about the terms and conditions of a litigation funding arrangement. While some courts have entered protective orders that specifically address litigation funding, such orders are not standard and cannot be assumed.

The privilege and confidentiality risks associated with the Resolute term sheet are difficult to quantify precisely, but they represent a meaningful and potentially outcome-determinative source of risk that is entirely avoidable if OWS self-funds the litigation.

E. Reputational and Relationship Considerations

Several reputational and relationship considerations further support the recommendation to decline the Resolute term sheet.

signaling to the Defendant. The involvement of a third-party litigation funder may signal to Lumos and its counsel that OWS lacks the financial resources or institutional commitment to prosecute the litigation to a successful conclusion. This perception, whether or not accurate, could embolden Lumos's defense strategy by encouraging a war-of-attrition approach — filing extensive motions, seeking broad discovery, and otherwise increasing the cost and duration of the litigation in the hope that OWS or its funder will lose patience and accept an unfavorable settlement. In contrast, self-funding by a well-capitalized company backed by a major private equity fund sends a clear signal that OWS is prepared to litigate aggressively and patiently.

Vantage Point's Reputation. Vantage Point Capital Partners is a sophisticated and well-respected private equity sponsor with significant resources. The use of third-party litigation funding by a Vantage Point portfolio company could be perceived in the market as inconsistent with Vantage Point's reputation for backing its investments with adequate capital and support. While this reputational consideration is secondary to the financial and legal analysis, it is not irrelevant to the overall assessment.

Administrative Complexity. Calderwood & Harkness's fee arrangement with OWS is structured for a direct client relationship: blended hourly billing with a volume discount and a quarterly evergreen retainer. The introduction of a litigation funder adds a layer of administrative complexity to the billing and reporting process. Under the Resolute term sheet, C&H would be required to prepare quarterly litigation status reports for Resolute, provide copies of significant filings, make attorneys available for strategy briefings, and manage the tranche disbursement process. While none of these requirements is individually burdensome, their cumulative effect is to divert time and attention from the substantive prosecution of the case.

VI. ALTERNATIVE CONSIDERATIONS

In the course of preparing this analysis, I have also considered whether alternative funding structures might address any of the concerns raised by the Resolute term sheet.

A. Contingency or Hybrid Fee Arrangement with Calderwood & Harkness

Calderwood & Harkness's current fee arrangement with OWS is a blended hourly rate with a 10% volume discount and a quarterly evergreen retainer. An alternative approach would be for C&H to accept a partial contingency arrangement, under which the Firm would reduce its hourly fees in exchange for a percentage of any recovery. Such an arrangement would shift some of the litigation risk from OWS to C&H, providing a form of risk sharing that might be viewed as a partial substitute for third-party funding.

However, a contingency or hybrid fee arrangement has not been proposed by OWS and is not recommended at this time. C&H's institutional preference for patent infringement litigation of this nature is hourly billing, given the inherent uncertainty of claim construction outcomes and the significant investment of partner and associate time required to prosecute a complex patent case through trial. A contingency arrangement would alter the Firm's economic incentives in ways that could, in the view of some, compromise the independence of the Firm's legal judgment. Moreover, the existing $100,000 quarterly evergreen retainer structure provides sufficient cash flow predictability for the Firm, and the 10% volume discount already reflects a meaningful fee concession by C&H.

Accordingly, the current hourly fee arrangement is appropriate and should be maintained.

B. Partial Funding at a Lower Level

OWS could, in theory, approach Resolute about a smaller funding commitment — for example, $1.5 million rather than $3.0 million — in an effort to reduce the cost of funding while still obtaining some degree of risk mitigation. However, based on our experience with litigation funders and our review of the Resolute term sheet, a reduction in the commitment amount would not materially alter the economics or control terms of the arrangement. Resolute would almost certainly insist on a similar return multiple (3.0× or higher) and similar approval rights on a smaller commitment. The 3.0× return multiple on $1.5 million would yield a $4.5 million first-dollar return, and the 15% residual participation would remain in effect above that threshold.

More fundamentally, the administrative, privilege, and signaling costs of any funder involvement remain constant regardless of the funding amount. The burden of quarterly reporting, strategy briefings, and privilege management does not scale with the dollar value of the funding commitment. Given that OWS has the capacity to self-fund the entire $4.2 million budget, there is no compelling reason to accept even a reduced level of funder involvement.

VII. RECOMMENDATION

Based on the foregoing analysis, I recommend that OWS decline the Resolute Litigation Finance term sheet and proceed with self-funding of the Optiwave Semiconductor Corp. v. Lumos Photonics, Inc. patent infringement litigation, with the $4.2 million Board-approved budget funded through OWS's existing capital resources, supported by Vantage Point Capital Partners Fund IV, LP.

This recommendation rests on five independent but mutually reinforcing grounds:

1. Economics. The 3.0× return multiple and 15% residual participation represent an extremely high cost of capital that materially dilutes OWS's expected recovery in all positive-outcome scenarios. In a $75 million recovery, Resolute's total take of $18.72 million exceeds four times the amount funded, reducing OWS's net recovery by nearly $19 million. In a moderate $25 million settlement, Resolute captures more of the proceeds than OWS. The only scenario in which Resolute funding provides a net benefit to OWS is the zero-recovery scenario — the least desirable litigation outcome and, based on the strength of the infringement case, one that we believe is unlikely.

2. Capacity. OWS and Vantage Point have ample capacity to self-fund the $4.2 million litigation budget. The budget represents approximately 2.2% of OWS's annual revenue and approximately 0.2% of Vantage Point Fund IV's committed capital. Both OWS management and the Vantage Point board representatives have confirmed their willingness to support the litigation budget from existing resources. There is no financial necessity for third-party funding.

3. Control. Resolute's approval rights over settlement, counsel selection, and significant strategy decisions are inconsistent with OWS's and Vantage Point's strongly expressed desire for unfettered litigation control. The settlement approval threshold of $15 million is particularly concerning because it could prevent OWS from accepting a rational settlement in the event of adverse litigation developments.

4. Privilege Risk. The unsettled state of the law regarding the application of the common interest doctrine to litigation funder communications, particularly in the Ninth Circuit, creates a meaningful and potentially outcome-determinative risk of privilege waiver. If Lumos's counsel, Victoria Ashworth of Brannick Howell & Stein LLP, were to successfully compel discovery of funder communications, the resulting disclosure could materially damage OWS's litigation position.

5. signaling. The involvement of a third-party funder may be perceived by Lumos and its advisors as a sign of OWS's financial constraints, potentially emboldening the defense and encouraging a war-of-attrition litigation strategy. Self-funding by a well-capitalized, PE-backed company sends a far stronger signal of commitment and resolve.

Recommended Next Steps. I recommend the following actions:

(a) Alan Ngo should inform Resolute Litigation Finance, LP of OWS's decision to decline the term sheet. The response should be brief, courteous, and non-committal — thanking Resolute for its interest, declining the proposal without extensive explanation, and preserving the relationship for potential consideration in future matters where the economics and circumstances might differ.

(b) This analysis should be presented to the OWS Board of Directors at the May 25, 2022 litigation strategy presentation. The Board should be informed of the Resolute approach, the terms of the term sheet, the financial comparison, and the basis for the recommendation to decline. The self-funding decision should be memorialized in the Board minutes.

(c) Calderwood & Harkness should proceed with final preparation of the complaint for filing in the Northern District of California, consistent with the litigation timeline previously discussed with OWS's General Counsel, Margaret Liu.

I am available to discuss this memorandum and its recommendations at your convenience.

VIII. ENCLOSURES AND ATTACHMENTS

The following materials are enclosed with this memorandum for reference:

Attachment A: Resolute Litigation Finance, LP — Term Sheet (dated approximately May 10, 2022). The complete term sheet as received by Calderwood & Harkness, consisting of twelve pages plus exhibits. This attachment is subject to the confidentiality provisions set forth in the cover letter accompanying the term sheet.

Attachment B: Financial Scenario Analysis — Self-Funding vs. Resolute Funding (Summary Table). A detailed spreadsheet setting forth the four recovery scenarios modeled in Section V.A of this memorandum, including supporting calculations for the waterfall distributions, effective tax rates, and implied returns to Resolute under each scenario.

Attachment C: Clearpath IP Valuation Services, Inc. — Patent Portfolio Valuation Summary (for reference re: expected litigation value). An executive summary of the Clearpath valuation report, including the portfolio-level valuation of $215 million and the individual valuations of the four asserted patents totaling $42.8 million. The full Clearpath report is maintained in the master case file and is available upon request.

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum, including all attachments, is protected by the attorney-client privilege and the work product doctrine. It has been prepared by counsel in anticipation of litigation and for the purpose of providing legal advice. Any unauthorized disclosure, copying, or distribution is strictly prohibited.

Timekeeper	Role	Standard Rate	Effective Rate (10% discount)
Alan Ngo	Responsible Partner	$1,150/hr	$1,035/hr
Marcus Delgado	Billing Partner	$1,050/hr	$945/hr
Farrah Siddiqui	Senior Associate	$785/hr	$706.50/hr
Thomas Bauer	Associate	$625/hr	$562.50/hr
Scenario	Recovery	Net to OWS (Self-Funded)	Net to OWS (Resolute-Funded)	Cost of Resolute Funding	Effective Tax on Recovery
1: Successful Outcome	$75.0M	$70.8M	$52.08M	$18.72M	24.96%
2: Moderate Settlement	$25.0M	$20.8M	$9.58M	$11.22M	44.88%
3: Small Settlement	$10.0M	$5.8M	~$0	~$5.8M	~58.0%
4: Zero Recovery	$0	($4.2M)	($1.2M)	($3.0M savings)	N/A

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege, the work product doctrine, and all other applicable privileges and protections. It is prepared in anticipation of litigation and for the purpose of providing legal advice to the client. Do not distribute, copy, or disclose this memorandum or its contents to any person or entity without the prior written authorization of Calderwood & Harkness LLP. Inadvertent disclosure does not constitute a waiver of any applicable privilege.
INTERNAL MEMORANDUM
CALDERWOOD & HARKNESS LLP
Date: May 20, 2022
To: Alan Ngo, Responsible Partner, intellectual Property Group, Calderwood & Harkness LLP
From: Marcus Delgado, Billing Partner, intellectual Property Group, Calderwood & Harkness LLP
Re: Litigation Funding Analysis — Review of Resolute Litigation Finance, LP Term Sheet for Partial Funding of Optiwave Semiconductor Corp. v. Lumos Photonics, Inc. Patent Infringement Litigation
Matter Number: 1014-00003
Client: Optiwave Semiconductor Corp.
I. EXECUTIVE SUMMARY
Calderwood & Harkness LLP ("C&H" or the "Firm") was retained by Optiwave Semiconductor Corp. ("OWS" or the "Company") on May 12, 2022, to prosecute a patent infringement action against Lumos Photonics, Inc. ("Lumos") in the United States District Court for the Northern District of California. The proposed action asserts four United States utility patents covering integrated waveguide coupling and photodetector architectures used in high-speed optical transceivers — technologies at the core of Lumos's recently launched product lines. The OWS Board of Directors, including representatives of majority shareholder Vantage Point Capital Partners Fund IV, LP ("Vantage Point"), authorized the litigation on April 28, 2022, with an approved budget of $4.2 million through trial.
Subsequent to our retention, and prior to the filing of the complaint, C&H received an unsolicited term sheet from Resolute Litigation Finance, LP ("Resolute"), a third-party litigation funder headquartered at 399 Park Avenue, 18th Floor, New York, NY 10022. The Resolute term sheet, dated on or about May 10, 2022, proposes to provide $3.0 million in partial funding of the litigation in exchange for a 3.0× return multiple on deployed capital, a 15% residual participation in recoveries above the return threshold, and certain approval and information rights over the conduct of the litigation.
This memorandum has been prepared at your request to provide a comprehensive analysis of the Resolute term sheet. It addresses the following matters: (i) the factual and legal background of the proposed litigation; (ii) the structure and terms of the Resolute funding proposal; (iii) a detailed financial comparison of self-funding versus Resolute-funded litigation economics across multiple recovery scenarios; (iv) an assessment of the control, privilege, confidentiality, and reputational implications of accepting third-party funding; and (v) a recommendation regarding the disposition of the Resolute term sheet.
Recommendation. For the reasons set forth in detail below, I recommend that OWS decline the Resolute Litigation Finance term sheet and proceed with self-funding of the litigation, supported by Vantage Point Capital Partners Fund IV, LP. This recommendation is grounded in the following considerations: (a) the 3.0× return multiple and 15% residual participation represent an extraordinarily high cost of capital that materially dilutes OWS's expected recovery in all positive-outcome scenarios; (b) OWS and Vantage Point have ample financial capacity to self-fund the Board-approved $4.2 million litigation budget, which represents approximately 0.2% of Vantage Point Fund IV's committed capital; (c) Resolute's approval rights over settlement, counsel selection, and significant strategy decisions are inconsistent with OWS's and Vantage Point's strongly expressed desire for unfettered litigation control; (d) the unsettled state of the law regarding privilege protection for communications shared with litigation funders, particularly in the Ninth Circuit, creates unnecessary and potentially outcome-determinative exposure; and (e) the involvement of a third-party funder may signal financial weakness to Lumos and its counsel, undermining OWS's litigation posture.
II. BACKGROUND
A. The Proposed Litigation
OWS is a Delaware corporation headquartered at 2775 Augustine Drive, Suite 400, San Jose, California 95054. The Company is a fabless semiconductor design company specializing in silicon photonics integrated circuits for data center interconnects and telecommunications applications. OWS does not fabricate its own silicon; rather, it designs and develops advanced photonic integrated circuit architectures that are manufactured through foundry partnerships. OWS's products are used by major cloud computing providers and telecommunications equipment manufacturers to enable high-bandwidth, low-latency data transmission across optical networks.
OWS reported fiscal year 2022 revenue of $187.4 million and employs approximately 620 people, the majority of whom are engineers and researchers based at the Company's San Jose headquarters and at a design center in Portland, Oregon. The Company has been profitable on an adjusted EBITDA basis for the past three fiscal years and maintains a strong balance sheet with adequate cash reserves for ongoing operations.
OWS holds a substantial intellectual property portfolio comprising 87 issued United States utility patents and 14 pending patent applications. The portfolio is concentrated in three core technology areas: (i) waveguide coupling architectures for silicon photonics platforms; (ii) germanium-on-silicon photodetectors with enhanced responsivity characteristics; and (iii) modulator driver architectures for high-speed silicon photonic Mach-Zehnder modulators. This portfolio represents the culmination of more than a decade of research and development by OWS's founding team and its engineering organization.
Prior to the commencement of this litigation, OWS engaged Clearpath IP Valuation Services, Inc. to conduct an independent valuation of its patent portfolio. The valuation was led by Jennifer Armitage, CFA, CLP, a recognized expert in intellectual property valuation with particular experience in the semiconductor and photonics sectors. Clearpath's analysis concluded that the OWS patent portfolio has a portfolio-level fair market value of approximately $215 million. Of particular relevance to this memorandum, Clearpath valued the four patents proposed for assertion in this litigation at a combined value of approximately $42.8 million, reflecting their centrality to the silicon photonics transceiver market and their strength as enforcement assets.
The defendant, Lumos Photonics, Inc. ("Lumos"), is a Delaware corporation headquartered at 9400 McNeil Drive, Building 7, Austin, Texas 78758. Lumos is a publicly traded company listed on the Nasdaq Stock Market under the ticker symbol "LMPH." For fiscal year 2022, Lumos reported revenue of approximately $312.8 million and employs approximately 1,450 people. As of the anticipated filing date, Lumos's market capitalization is approximately $1.87 billion. Lumos designs, manufactures, and markets optical transceiver modules and optical engine sub-assemblies for data center and telecommunications applications. The largest institutional shareholder of Lumos is Ridgeline Asset Management, LLC, which holds an approximate 9.2% equity stake.
The accused products in this action are: (i) the LumosBridge™ 800G Optical Engine, which carries a unit price in the range of $1,200 to $1,800 and was first shipped to customers in the first quarter of 2022; and (ii) the LumosEdge™ 400ZR+ Pluggable Transceiver, which carries a unit price in the range of $600 to $900 and has been in commercial production since the third quarter of 2021. Based on OWS's market intelligence and publicly available financial data, the combined accused product revenue for calendar year 2022 is estimated at approximately $148.6 million. The pre-suit damages period — spanning the first and second quarters of 2022 — accounts for approximately $62.3 million of that total.
OWS's technical team, working with outside technical consultants, has conducted a detailed claim-by-claim mapping of the accused Lumos products against the asserted patent claims. That analysis, which was presented to the Board as part of the April 28, 2022 litigation authorization meeting, concludes that both accused products practice multiple claims of each of the four asserted patents. The infringement analysis is supported by publicly available product datasheets, Lumos's published technical papers and conference presentations, teardown analyses of purchased Lumos products, and reverse engineering of the optical and electronic subsystems.
B. The Patents-in-Suit
The four United States utility patents proposed for assertion in this action are summarized below:
U.S. Patent No. 10,234,567 (the "'567 Patent"). Entitled "Integrated Waveguide Coupler with Tapered Mode Converter for Silicon Photonics Platforms," the '567 Patent was filed on March 14, 2017, and issued on March 19, 2019. The named inventors are Dr. Kevin Fong, Dr. Priya Ramanathan, and Hideo Tanaka. The '567 Patent is directed to a novel waveguide coupler architecture that utilizes a tapered mode converter to achieve low-loss optical coupling between an external optical fiber and a silicon photonic waveguide. The claimed invention addresses a long-standing challenge in silicon photonics — the significant mode-field mismatch between standard single-mode optical fibers and sub-micron silicon waveguides. The '567 Patent contains 24 claims, including 4 independent claims.
U.S. Patent No. 10,891,234 (the "'234 Patent"). Entitled "Germanium-on-Silicon Photodetector with Graded Buffer Layer for Enhanced Responsivity," the '234 Patent was filed on September 8, 2017, and issued on January 14, 2021. The named inventors are Dr. Kevin Fong and Dr. Amara Osei. The '234 Patent discloses and claims a germanium-on-silicon photodetector structure that employs a graded silicon-germanium buffer layer to reduce threading dislocation density at the germanium-silicon interface, thereby enhancing photodetector responsivity and reducing dark current. The '234 Patent contains 18 claims, including 3 independent claims.
U.S. Patent No. 11,045,678 (the "'678 Patent"). Entitled "Multi-Channel Optical Transceiver with Integrated Wavelength-Division Multiplexing on Silicon," the '678 Patent was filed on June 22, 2018, and issued on June 29, 2021. The named inventors are Dr. Priya Ramanathan, Dr. Amara Osei, and Liwei Zhang. The '678 Patent is directed to a multi-channel transceiver architecture that integrates wavelength-division multiplexing (WDM) functionality directly onto a silicon photonic chip, eliminating the need for discrete external multiplexing components and enabling higher-density optical interconnects. The '678 Patent contains 22 claims, including 3 independent claims.
U.S. Patent No. 11,312,890 (the "'890 Patent"). Entitled "Driver Circuit Architecture for High-Speed Silicon Photonic Mach-Zehnder Modulators," the '890 Patent was filed on November 15, 2018, and issued on April 26, 2022. The named inventors are Dr. Kevin Fong and Rajesh Iyer. The '890 Patent claims a novel driver circuit architecture optimized for high-speed Mach-Zehnder modulator structures in silicon photonics, addressing signal integrity and power consumption challenges at data rates of 100 Gbps per lane and above. The '890 Patent contains 20 claims, including 4 independent claims. Notably, the '890 Patent issued less than one month prior to the date of this memorandum, and its claims were allowed without any rejections on prior art grounds during prosecution.
All four patents are currently assigned to OWS and are in force. Maintenance fees are current. No inter partes review, post-grant review, or ex parte reexamination proceedings have been initiated against any of the four patents as of the date of this memorandum, although we anticipate that Lumos will likely petition for inter partes review of one or more of these patents following the filing of the complaint.
C. Projected Damages and Litigation Economics
Based on our preliminary analysis of the damages landscape, OWS's claimed damages are believed to exceed $75 million. This estimate is grounded in a reasonable royalty theory of damages under 35 U.S.C. § 284, applying the Georgia-Pacific factor framework. Specifically, the damages analysis contemplates an estimated royalty rate of 7.5% applied to the accused product revenue base. Applying this rate to the estimated calendar year 2022 accused product revenue of $148.6 million yields a base annual royalty of approximately $11.145 million. The total claim value is enhanced by: (i) the pre-suit damages period, during which Lumos was on notice of OWS's patent rights by virtue of the cease-and-desist letter sent on March 15, 2022; (ii) post-suit damages accruing through the anticipated trial date; and (iii) the potential for willfulness enhancement of up to three times the damages found, pursuant to 35 U.S.C. § 284, given Lumos's apparent knowledge of OWS's patent portfolio and the absence of any opinion of counsel or design-around effort.
The Board-approved litigation budget of $4.2 million encompasses all anticipated attorneys' fees, expert costs, and litigation disbursements through trial. This budget was developed by C&H in consultation with OWS's General Counsel, Margaret Liu, and was presented to and approved by the Board at its April 28, 2022 meeting.
The fee arrangement between OWS and Calderwood & Harkness provides for a blended hourly rate with a 10% volume discount on the Firm's standard rates. OWS maintains a $100,000 evergreen retainer that is replenished on a quarterly basis. The applicable standard billing rates and effective rates (after the 10% discount) for the core litigation team are as follows:
In addition to attorneys' fees, the litigation budget includes estimated expert costs of $400,000 to $500,000 through trial. The Firm has identified and engaged, subject to OWS's approval, two experts for this matter: (i) Dr. Harold Whitfield of Whitfield Technical Consulting Group, Inc., who will serve as OWS's technical expert on infringement, validity, and claim construction; and (ii) Dr. Lawrence Kessler of Apex Claim Analytics LLC, who will serve as OWS's damages expert. Both experts are experienced in patent litigation in the semiconductor and photonics fields and have testified in prior proceedings before the Northern District of California and the International Trade Commission.
D. OWS Ownership and Capital Structure
OWS is majority-owned by Vantage Point Capital Partners Fund IV, LP ("Vantage Point" or "Fund IV"), which holds approximately 62% of the Company's fully diluted equity. The general partner of Fund IV is Vantage Point Capital GP IV, LLC, headquartered at 2600 Sand Hill Road, Suite 200, Menlo Park, California 94025. Vantage Point Fund IV is a $2.1 billion private equity fund with a 2018 vintage year. The fund's managing partner is Douglas Fairbanks III, and the operating partner responsible for the semiconductor sector is Rebecca Torres.
Vantage Point's total equity investment in OWS, across Series C and Series D preferred stock rounds, is approximately $74.5 million. Vantage Point holds three of the seven seats on the OWS Board of Directors, giving it significant but not unilateral control over major corporate decisions. The remaining equity in OWS is held by the Company's founders — Dr. Priya Ramanathan and Dr. Kevin Fong — along with members of the management team and certain angel investors who participated in the Company's earlier financing rounds.
OWS's primary lending relationship is with First Pacific Commerce Bank, N.A. ("FPCB"), located at 345 Montgomery Street, San Francisco, California 94104. OWS maintains a $40 million revolving credit facility with FPCB, secured by a blanket lien on the Company's intellectual property assets. While the credit facility provides additional liquidity, drawing on it for the purpose of funding litigation expenses may raise issues under the financial covenants governing the facility, and any such draw would require separate analysis and potentially the consent of FPCB. For the purposes of this memorandum, the analysis of OWS's capacity to self-fund the litigation does not assume any draw on the FPCB credit facility.
The capital structure and financial position of OWS and Vantage Point are directly relevant to the analysis of whether third-party litigation funding is necessary or advisable. As discussed in greater detail in Section V.B below, the Board-approved litigation budget of $4.2 million is well within OWS's operational capacity and represents an immaterial amount relative to Vantage Point Fund IV's committed capital.
III. RESOLUTE LITIGATION FINANCE, LP — OVERVIEW
Resolute Litigation Finance, LP ("Resolute") is a Delaware limited partnership headquartered at 399 Park Avenue, 18th Floor, New York, New York 10022. Resolute is a third-party litigation funder that specializes in providing non-recourse financing for commercial litigation and intellectual property enforcement actions. Based on publicly available information and our own review, Resolute manages several hundred million dollars in committed capital across multiple fund vehicles and has funded patent infringement cases, antitrust claims, and complex commercial disputes.
Resolute approached OWS and Calderwood & Harkness with an unsolicited expression of interest in funding the contemplated patent infringement action against Lumos. Based on our understanding, Resolute became aware of the potential litigation through market intelligence sources; specifically, several silicon photonics trade publications reported in late March and early April 2022 that OWS had sent a cease-and-desist letter to Lumos on March 15, 2022, alleging infringement of multiple patents related to waveguide coupling and photodetector technologies. It is not uncommon for litigation funders to monitor trade press, patent assignment databases, and litigation dockets for opportunities, and Resolute's outreach is consistent with that practice.
The Resolute term sheet was received by Calderwood & Harkness on or about May 10, 2022 — two days before C&H was formally retained by OWS to prosecute the action. The timing of the term sheet, while coincidental, does not appear to reflect any improper access to privileged information. Nonetheless, the fact that Resolute was able to identify and pursue this opportunity so quickly underscores the transparency of the marketplace and the extent to which OWS's enforcement activities may already be visible to market participants, including Lumos and its advisors.
We have reviewed publicly available information regarding Resolute's track record, management team, and standard deal terms. While Resolute has funded a number of successful patent enforcement campaigns, the terms proposed in this instance — particularly the 3.0× return multiple and the breadth of the approval rights — are at the higher end of the range we have observed in the third-party litigation funding market for patent infringement cases with the profile of this action. This observation informs the financial analysis set forth in Section V below.
IV. SUMMARY OF RESOLUTE TERM SHEET — KEY TERMS
The following is a summary of the material terms of the Resolute term sheet. This summary is not intended to be exhaustive and is qualified in its entirety by the term sheet itself, which is enclosed as Attachment A. We note that the term sheet is a non-binding indication of Resolute's proposed terms and would be subject to further negotiation and the execution of a definitive funding agreement.
A. Funding Amount and Structure
Resolute proposes to commit $3.0 million to fund a portion of the litigation costs, including attorneys' fees, expert costs, and litigation disbursements. This amount represents approximately 71% of the Board-approved litigation budget of $4.2 million. OWS would remain responsible for funding the balance of litigation costs in excess of $3.0 million, which, based on the current budget, is estimated at approximately $1.2 million.
The proposed funding would be disbursed in four equal tranches of $750,000 each, tied to the achievement of specified litigation milestones:
(i) Tranche 1 — $750,000: Payable upon execution of the definitive funding agreement and the filing of the complaint;
(ii) Tranche 2 — $750,000: Payable upon completion of claim construction briefing (i.e., the filing of all Markman hearing briefs and supporting materials);
(iii) Tranche 3 — $750,000: Payable upon completion of fact discovery (including the close of all fact depositions and the expiration of the fact discovery deadline set by the court);
(iv) Tranche 4 — $750,000: Payable upon the commencement of trial (i.e., the first day of jury selection or, in a bench trial, the first day of the presentation of evidence).
Funds disbursed by Resolute would be applied first to C&H invoices for fees and costs, and thereafter to expert fees and other litigation disbursements. This sequencing is significant because it means that Resolute's capital would effectively subsidize C&H's fees first, with expert costs funded out of the remaining balance or by OWS directly. Depending on the pace of fee accrual relative to the milestone schedule, there could be periods during the litigation when OWS is required to fund C&H fees and expert costs from its own resources while awaiting the next tranche disbursement.
B. Return Multiple and Waterfall
The economic terms of the Resolute proposal are structured around a return multiple and a residual participation mechanism. Specifically:
Return Multiple. Resolute is entitled to a return of 3.0× on its total deployed capital from any litigation proceeds. If Resolute deploys the full $3.0 million commitment, its first-dollar return entitlement would be $9.0 million. This return is calculated on deployed (i.e., actually disbursed) capital, not on the total commitment. If the litigation settles or concludes before all four tranches are disbursed, the return multiple applies only to the capital that has been drawn.
Residual Participation. If the total recovery from the litigation — whether by way of settlement, judgment, or otherwise — exceeds $9.0 million, Resolute is entitled to an additional 15% of the amount by which the total recovery exceeds $9.0 million. This residual participation is uncapped and would apply to any incremental recovery regardless of its magnitude.
The waterfall governing the distribution of any settlement or judgment proceeds is as follows:
(1) First: Reimbursement of OWS's self-funded litigation costs (estimated at $1.2 million based on the current budget);
(2) Second: Payment of Resolute's 3.0× return on deployed capital ($9.0 million on full deployment);
(3) Third: Payment of 15% of the remaining proceeds (above $9.0 million) to Resolute; and
(4) Fourth: Payment of the balance to OWS.
In the event of a walk-away or zero-recovery scenario — whether resulting from an adverse judgment, a voluntary dismissal, or otherwise — Resolute bears its funded amount as a loss. The funding is non-recourse to OWS, meaning that OWS has no obligation to repay any portion of Resolute's deployed capital in a zero-recovery outcome. This non-recourse feature is the principal economic benefit of litigation funding and represents the risk that Resolute assumes in exchange for the return multiple and residual participation described above.
C. Control and Approval Rights
The Resolute term sheet includes a set of approval and control rights that would grant Resolute significant influence over the conduct of the litigation. The specific approval rights are as follows:
(i) Selection and Replacement of Lead Counsel. Resolute retains approval rights over the selection and replacement of lead litigation counsel. While OWS's current selection of Calderwood & Harkness would presumably be approved as part of the initial funding agreement, any subsequent change in lead counsel — whether initiated by OWS or necessitated by circumstances — would require Resolute's consent.
(ii) Settlement Approval. Resolute retains approval rights over the settlement of claims for less than $15 million. This means that if OWS and C&H determine that a settlement at or below $15 million is in OWS's best interests — for example, following an adverse claim construction ruling or other litigation development — OWS could not accept such a settlement without Resolute's consent.
(iii) Voluntary Dismissal or Abandonment. Resolute retains approval rights over any voluntary dismissal or abandonment of claims, whether in whole or in part.
(iv) Significant Litigation Strategy Decisions. Resolute retains approval rights over significant litigation strategy decisions, including but not limited to venue transfer motions and claim narrowing decisions. The term sheet does not define "significant litigation strategy decisions" with precision, creating ambiguity about the scope of Resolute's approval authority.
Notwithstanding these approval rights, the term sheet provides that OWS retains day-to-day litigation management through its chosen counsel, Calderwood & Harkness. This distinction between "day-to-day management" and "significant strategy decisions" is, however, inherently imprecise and is likely to give rise to disputes during the course of the litigation.
In addition to the approval rights, Resolute is entitled to quarterly litigation status reports prepared by C&H, copies of all significant filings (including motions, briefs, and court orders), and access to C&H attorneys for strategy briefings. Resolute also has the right to attend, as an observer, any mediation or settlement conference. These information and observation rights, while less intrusive than the approval rights, create additional administrative burden and raise privilege and confidentiality concerns discussed in Section V.D below.
D. Information Rights and Confidentiality
The Resolute term sheet provides Resolute with broad information rights, including the right to review all non-privileged litigation materials, expert reports, and key discovery documents. These information rights are intended to enable Resolute to monitor the progress of the litigation and to make informed decisions regarding the exercise of its approval rights.
A critical issue raised by these information rights is the question of whether sharing privileged materials — including attorney-client communications and attorney work product — with Resolute would constitute a waiver of the attorney-client privilege or work product protection. The term sheet contemplates that certain privileged communications may be shared with Resolute under the common interest doctrine, which permits the sharing of privileged information among parties with a common legal interest without waiving the privilege. However, the application of the common interest doctrine to communications between a litigant and its litigation funder is not settled law in all jurisdictions, and the question has not been definitively resolved by the Ninth Circuit Court of Appeals — the circuit encompassing the Northern District of California, which is the anticipated venue for this action. This issue is analyzed in greater detail in Section V.D below.
The term sheet also requires Resolute to be bound by confidentiality provisions and to execute a confidentiality agreement that is compatible with any court-entered protective order. While this is a standard provision in litigation funding arrangements, its effectiveness depends in part on whether the court's protective order specifically contemplates and permits the disclosure of information to litigation funders, which cannot be assumed.
E. Term and Termination
The funding agreement contemplated by the term sheet would terminate upon the final resolution of the litigation, whether by judgment, settlement, or voluntary dismissal. The term sheet also addresses the circumstances under which each party may terminate the arrangement prior to final resolution:
Resolute's Termination Rights. Resolute may terminate the funding arrangement if: (i) OWS materially breaches the funding agreement; (ii) a court enters a final, non-appealable adverse judgment in the litigation; or (iii) OWS refuses to follow reasonable litigation strategy recommendations made by Resolute. The inclusion of item (iii) is notable because it effectively gives Resolute a termination right triggered by a disagreement over litigation strategy, which could be exercised in situations where OWS and C&H believe that a particular strategic approach is in OWS's best interest but Resolute disagrees.
Upon termination by Resolute, Resolute forfeits its deployed capital — consistent with the non-recourse nature of the funding — but OWS becomes immediately responsible for all future litigation costs without the benefit of any further Resolute funding.
OWS's Termination Rights. OWS may terminate the funding arrangement at any time, but only upon repayment of Resolute's deployed capital plus a 1.5× return. This buyout provision means that if OWS wishes to extricate itself from the funding arrangement after Resolute has deployed the full $3.0 million, OWS would be required to pay Resolute $4.5 million. This buyout cost is in addition to the litigation costs that OWS would continue to bear going forward.
The asymmetry of the termination provisions is noteworthy. Resolute can walk away with no further obligation if it loses confidence in the litigation, while OWS can exit the arrangement only by paying a premium over deployed capital. This structure is common in third-party litigation funding but is nonetheless unfavorable to the funded party.
V. ANALYSIS: SELF-FUNDING VS. RESOLUTE FUNDING
A. Financial Comparison
The core question presented by the Resolute term sheet is whether the economics of third-party funding justify the cost, given OWS's capacity to self-fund the litigation. To address this question, I have modeled four recovery scenarios that span the range of reasonably probable outcomes. The detailed scenario analysis is presented in Attachment B; the key results are summarized below.
1. Scenario 1: Successful Outcome — $75 Million Recovery
This scenario assumes that OWS achieves its targeted recovery of $75 million, whether through a favorable judgment or a settlement at or near the claimed damages amount.
Self-Funded. Under a self-funded approach, OWS bears the full $4.2 million litigation budget and retains the entirety of the $75 million recovery. Net to OWS: approximately $70.8 million.
Resolute-Funded. Under the Resolute term sheet, proceeds would be distributed as follows:
•  OWS reimbursement of self-funded costs: $1.2 million
•  Resolute 3.0× return: $9.0 million (3.0 × $3.0 million deployed)
•  Resolute 15% residual: 15% × ($75.0M − $9.0M − $1.2M) = 15% × $64.8M = $9.72 million
•  Total Resolute take: $18.72 million
•  Net to OWS: $75.0M − $4.2M (total litigation costs) − $18.72M (Resolute take) = $52.08 million
Cost of Resolute Funding. In this scenario, the cost of Resolute funding to OWS is $18.72 million. This represents a 24.96% effective tax on the gross recovery, or, stated differently, a 624% effective return to Resolute on its $3.0 million deployed capital. OWS's net recovery is reduced by approximately $18.72 million — a sum that far exceeds the $3.0 million in risk capital provided by Resolute and that would otherwise flow entirely to OWS and its shareholders.
2. Scenario 2: Moderate Settlement — $25 Million Recovery
This scenario assumes a moderate settlement of $25 million, which might result from a partially favorable claim construction ruling or other litigation developments that narrow the case but do not eliminate OWS's leverage.
Self-Funded. OWS bears the full $4.2 million budget. Net to OWS: $25.0M − $4.2M = $20.8 million.
Resolute-Funded. Distribution of proceeds:
•  OWS reimbursement of self-funded costs: $1.2 million
•  Resolute 3.0× return: $9.0 million
•  Resolute 15% residual: 15% × ($25.0M − $9.0M − $1.2M) = 15% × $14.8M = $2.22 million
•  Total Resolute take: $11.22 million
•  Net to OWS: $25.0M − $4.2M − $11.22M = $9.58 million
Cost of Resolute Funding. The cost of Resolute funding in this scenario is $11.22 million, representing a 44.88% effective tax on gross recovery. OWS's net recovery is reduced from $20.8 million (self-funded) to $9.58 million (Resolute-funded) — a reduction of more than 53%. At a $25 million recovery level, Resolute captures more of the litigation proceeds than OWS itself.
3. Scenario 3: Small Settlement — $10 Million Recovery
This scenario assumes a small settlement of $10 million, which might result from an unfavorable claim construction ruling, an adverse inter partes review outcome, or other developments that significantly weaken OWS's case.
Self-Funded. OWS bears the full $4.2 million budget. Net to OWS: $10.0M − $4.2M = $5.8 million.
Resolute-Funded. Distribution of proceeds:
•  OWS reimbursement of self-funded costs: $1.2 million
•  Resolute 3.0× return: $9.0 million
•  Resolute 15% residual: 15% × ($10.0M − $9.0M − $1.2M) = 15% × (−$0.2M) = $0 (the calculation yields a negative number, so no additional residual participation is payable)
•  Total Resolute take: $9.0 million
•  Net to OWS: $10.0M − $4.2M (total litigation costs, of which $1.2M is self-funded) − $9.0M (Resolute take) = −$3.2 million on a gross basis
In practical terms, OWS would not owe Resolute more than the litigation proceeds allow. However, after application of the waterfall, OWS's $1.2 million in self-funded costs is reimbursed first, Resolute's $9.0 million entitlement is then satisfied from the remaining $8.8 million of proceeds (leaving a $200,000 shortfall in Resolute's return, which would be absorbed by Resolute under the non-recourse structure), and nothing remains for OWS. OWS's effective net position is approximately zero (retaining only the $1.2 million reimbursement offset against the $1.2 million already spent), while also having incurred $4.2 million in total litigation costs.
Cost of Resolute Funding. This scenario starkly illustrates the punitive effect of the 3.0× return multiple on lower-value outcomes. Resolute's return structure consumes virtually the entirety of the recovery, leaving OWS with no net benefit from the litigation despite a $10 million settlement.
4. Scenario 4: Zero Recovery (Walk-Away or Adverse Judgment)
This scenario assumes that the litigation results in no recovery to OWS — whether because of a final adverse judgment, a voluntary dismissal, or an unfavorable resolution of invalidity or non-infringement challenges.
Self-Funded. OWS absorbs the full $4.2 million in litigation costs as a total loss.
Resolute-Funded. Resolute absorbs its $3.0 million in deployed capital as a loss, consistent with the non-recourse structure. OWS absorbs only its $1.2 million self-funded portion. OWS's total loss is $1.2 million rather than $4.2 million.
OWS Savings. In this scenario, OWS saves $3.0 million by virtue of the non-recourse funding. This is the only scenario in which Resolute funding provides a net economic benefit to OWS. However, it is also, by definition, the least desirable litigation outcome — one in which OWS's patent rights are not vindicated and no monetary recovery is obtained.
The following summary table compiles the results of the four scenarios:
The financial analysis demonstrates that Resolute funding is favorable to OWS only in the zero-recovery scenario, where it functions as a form of insurance against total loss. In every scenario involving a positive recovery, the cost of Resolute funding is substantial and disproportionate to the capital provided. In the most likely successful outcome (Scenario 1), Resolute's $18.72 million take represents more than six times its deployed capital. In the moderate settlement scenario, Resolute captures more value than OWS. And in the small settlement scenario, Resolute's return structure effectively eliminates OWS's net recovery entirely.
B. OWS/Vantage Point Capacity to Self-Fund
The financial analysis set forth above would counsel against Resolute funding even if OWS lacked the resources to self-fund the litigation. However, the case against Resolute funding is further strengthened by the fact that OWS and its principal shareholder, Vantage Point Capital Partners Fund IV, LP, have ample capacity to self-fund the Board-approved litigation budget of $4.2 million.
OWS itself generates annual revenue of $187.4 million, operates at positive cash flow, and is operationally solvent. While the Company maintains a $40 million revolving credit facility with First Pacific Commerce Bank, N.A., which could provide an additional source of liquidity if needed, drawing on the credit facility for litigation expenses may raise covenant compliance issues under the credit agreement and is not contemplated or recommended at this time. The $4.2 million litigation budget represents approximately 2.2% of OWS's annual revenue — a meaningful but manageable expenditure for a company of OWS's size and financial profile.
More significantly, OWS's majority shareholder, Vantage Point Capital Partners Fund IV, LP, has $2.1 billion in committed capital. The $4.2 million litigation budget represents approximately 0.2% of the fund's total committed capital — an amount that is, by any measure, immaterial to Vantage Point. Vantage Point has invested $74.5 million in OWS and has a direct financial interest in maximizing the value of OWS's intellectual property portfolio. The successful prosecution of this patent infringement action would protect and enhance the value of that investment.
We have confirmed through conversations with OWS's General Counsel, Margaret Liu, that Vantage Point's Operating Partner, Rebecca Torres, and Managing Partner, Douglas Fairbanks III, have indicated their willingness to support the litigation budget through OWS's existing capital resources. The Board's April 28, 2022 authorization of the $4.2 million budget was made with the full support of the Vantage Point board representatives, and there is no indication that OWS faces any constraint on its ability to fund the litigation from internal resources.
In sum, the economic rationale for third-party litigation funding — namely, to provide capital that the litigant cannot otherwise access — is simply not present here. OWS has the means to self-fund, and the cost of external capital from Resolute is grossly disproportionate to the benefit received.
C. Control Considerations
Beyond the financial analysis, the control provisions of the Resolute term sheet raise significant strategic and practical concerns that independently counsel against acceptance of the term sheet.
Settlement Approval Rights. Resolute's veto right over settlements below $15 million creates a particularly dangerous strategic constraint. Patent infringement litigation is inherently uncertain, and the outcome of any individual case can be significantly affected by developments that are difficult to predict at the outset — including claim construction rulings, inter partes review outcomes, summary judgment motions, and changes in the technology market. If any of these developments materially weakens OWS's case, a rational litigant might conclude that a settlement in the range of $5 million to $15 million represents a favorable outcome relative to the risk-adjusted expected value of continuing to trial. Under the Resolute term sheet, OWS could not accept such a settlement without Resolute's consent. Resolute's interests in this situation would diverge from OWS's: because Resolute's non-recourse structure means that it loses its deployed capital in a zero-recovery outcome, Resolute has an incentive to continue litigating even when the risk-adjusted expected value of doing so is negative for OWS, because the downside to Resolute is capped at its deployed capital while the upside includes its 3.0× return multiple and 15% residual participation.
Counsel Selection and Replacement. Resolute's approval right over the selection and replacement of lead counsel is unusual in scope and potentially intrusive to the attorney-client relationship. The engagement between OWS and Calderwood & Harkness was negotiated directly between the Company and the Firm, based on OWS's and Vantage Point's confidence in C&H's intellectual property litigation capabilities. Any funder interference with this relationship — whether through the initial approval process or through a subsequent disagreement about counsel performance — would undermine the trust and independence that are essential to effective legal representation. Moreover, the approval right creates the risk that Resolute could use its counsel-selection authority as leverage in disputes over settlement or strategy.
Significant Strategy Decisions. The term sheet's requirement that Resolute approve "significant litigation strategy decisions" — including venue transfer motions and claim narrowing — is both broad and imprecise. It is unclear from the term sheet what constitutes a "significant" decision as opposed to a "day-to-day" management decision. This ambiguity is likely to generate friction as the litigation progresses and could delay time-sensitive tactical decisions while approval from Resolute is sought.
OWS and Vantage Point Preference. Both OWS management and the Vantage Point board representatives have expressed a strong preference for retaining full and unfettered control over the prosecution of this litigation. The Board's authorization of the litigation on April 28, 2022 was predicated on the assumption that OWS and its chosen counsel would have complete autonomy to make all strategic and tactical decisions, including settlement decisions. The introduction of a third-party funder with approval rights over these decisions is fundamentally inconsistent with that expectation.
D. Privilege and Confidentiality Risks
The sharing of litigation strategy materials, attorney-client communications, and attorney work product with a litigation funder such as Resolute raises significant and, in the relevant jurisdiction, unresolved privilege concerns.
The attorney-client privilege protects confidential communications between a client and its attorney made for the purpose of obtaining or providing legal advice. The work product doctrine protects materials prepared by or for an attorney in anticipation of litigation. Both protections can be waived by voluntary disclosure of the protected material to a third party who does not share a common legal interest with the disclosing party.
The common interest doctrine (sometimes referred to as the "joint defense privilege" or "allied litigant doctrine") is an exception to the general waiver rule. It permits the sharing of privileged communications among parties who share a common legal interest without constituting a waiver of the privilege. Some courts have applied the common interest doctrine to communications between litigants and their litigation funders, on the theory that the funder and the funded party share a common interest in the successful outcome of the litigation.
However, the application of the common interest doctrine to litigation funding relationships is far from settled. Courts in different jurisdictions have reached conflicting conclusions, and the Ninth Circuit — which encompasses the Northern District of California, the anticipated venue for this action — has not definitively resolved the question. In the absence of clear Ninth Circuit authority, there is a meaningful risk that a court could conclude that the common interest doctrine does not apply to the Resolute funding relationship, and that the disclosure of privileged materials to Resolute constitutes a waiver of the privilege as to those materials.
If privilege were deemed waived as to communications shared with Resolute, the consequences could be severe. Lumos's counsel — Brannick Howell & Stein LLP, led by partner Victoria Ashworth, who is known in the patent litigation community for her aggressive and thorough litigation tactics — would likely seek discover the existence and terms of the funding arrangement, as well as any privileged communications that were shared with Resolute. Discovery of the funding arrangement could provide Lumos with valuable insights into OWS's litigation strategy, settlement parameters, and risk assessment. It could also be used to argue that OWS's litigation decisions are being driven by the funder's financial interests rather than by a good-faith belief in the merits of its patent claims.
Additionally, the protective order that the parties would negotiate and submit to the court at the outset of the litigation would not necessarily shield funder communications from discovery. Protective orders typically govern the handling of discovery materials produced by the parties; they do not create an independent basis for shielding otherwise discoverable information about the terms and conditions of a litigation funding arrangement. While some courts have entered protective orders that specifically address litigation funding, such orders are not standard and cannot be assumed.
The privilege and confidentiality risks associated with the Resolute term sheet are difficult to quantify precisely, but they represent a meaningful and potentially outcome-determinative source of risk that is entirely avoidable if OWS self-funds the litigation.
E. Reputational and Relationship Considerations
Several reputational and relationship considerations further support the recommendation to decline the Resolute term sheet.
signaling to the Defendant. The involvement of a third-party litigation funder may signal to Lumos and its counsel that OWS lacks the financial resources or institutional commitment to prosecute the litigation to a successful conclusion. This perception, whether or not accurate, could embolden Lumos's defense strategy by encouraging a war-of-attrition approach — filing extensive motions, seeking broad discovery, and otherwise increasing the cost and duration of the litigation in the hope that OWS or its funder will lose patience and accept an unfavorable settlement. In contrast, self-funding by a well-capitalized company backed by a major private equity fund sends a clear signal that OWS is prepared to litigate aggressively and patiently.
Vantage Point's Reputation. Vantage Point Capital Partners is a sophisticated and well-respected private equity sponsor with significant resources. The use of third-party litigation funding by a Vantage Point portfolio company could be perceived in the market as inconsistent with Vantage Point's reputation for backing its investments with adequate capital and support. While this reputational consideration is secondary to the financial and legal analysis, it is not irrelevant to the overall assessment.
Administrative Complexity. Calderwood & Harkness's fee arrangement with OWS is structured for a direct client relationship: blended hourly billing with a volume discount and a quarterly evergreen retainer. The introduction of a litigation funder adds a layer of administrative complexity to the billing and reporting process. Under the Resolute term sheet, C&H would be required to prepare quarterly litigation status reports for Resolute, provide copies of significant filings, make attorneys available for strategy briefings, and manage the tranche disbursement process. While none of these requirements is individually burdensome, their cumulative effect is to divert time and attention from the substantive prosecution of the case.
VI. ALTERNATIVE CONSIDERATIONS
In the course of preparing this analysis, I have also considered whether alternative funding structures might address any of the concerns raised by the Resolute term sheet.
A. Contingency or Hybrid Fee Arrangement with Calderwood & Harkness
Calderwood & Harkness's current fee arrangement with OWS is a blended hourly rate with a 10% volume discount and a quarterly evergreen retainer. An alternative approach would be for C&H to accept a partial contingency arrangement, under which the Firm would reduce its hourly fees in exchange for a percentage of any recovery. Such an arrangement would shift some of the litigation risk from OWS to C&H, providing a form of risk sharing that might be viewed as a partial substitute for third-party funding.
However, a contingency or hybrid fee arrangement has not been proposed by OWS and is not recommended at this time. C&H's institutional preference for patent infringement litigation of this nature is hourly billing, given the inherent uncertainty of claim construction outcomes and the significant investment of partner and associate time required to prosecute a complex patent case through trial. A contingency arrangement would alter the Firm's economic incentives in ways that could, in the view of some, compromise the independence of the Firm's legal judgment. Moreover, the existing $100,000 quarterly evergreen retainer structure provides sufficient cash flow predictability for the Firm, and the 10% volume discount already reflects a meaningful fee concession by C&H.
Accordingly, the current hourly fee arrangement is appropriate and should be maintained.
B. Partial Funding at a Lower Level
OWS could, in theory, approach Resolute about a smaller funding commitment — for example, $1.5 million rather than $3.0 million — in an effort to reduce the cost of funding while still obtaining some degree of risk mitigation. However, based on our experience with litigation funders and our review of the Resolute term sheet, a reduction in the commitment amount would not materially alter the economics or control terms of the arrangement. Resolute would almost certainly insist on a similar return multiple (3.0× or higher) and similar approval rights on a smaller commitment. The 3.0× return multiple on $1.5 million would yield a $4.5 million first-dollar return, and the 15% residual participation would remain in effect above that threshold.
More fundamentally, the administrative, privilege, and signaling costs of any funder involvement remain constant regardless of the funding amount. The burden of quarterly reporting, strategy briefings, and privilege management does not scale with the dollar value of the funding commitment. Given that OWS has the capacity to self-fund the entire $4.2 million budget, there is no compelling reason to accept even a reduced level of funder involvement.
VII. RECOMMENDATION
Based on the foregoing analysis, I recommend that OWS decline the Resolute Litigation Finance term sheet and proceed with self-funding of the Optiwave Semiconductor Corp. v. Lumos Photonics, Inc. patent infringement litigation, with the $4.2 million Board-approved budget funded through OWS's existing capital resources, supported by Vantage Point Capital Partners Fund IV, LP.
This recommendation rests on five independent but mutually reinforcing grounds:
1.  Economics. The 3.0× return multiple and 15% residual participation represent an extremely high cost of capital that materially dilutes OWS's expected recovery in all positive-outcome scenarios. In a $75 million recovery, Resolute's total take of $18.72 million exceeds four times the amount funded, reducing OWS's net recovery by nearly $19 million. In a moderate $25 million settlement, Resolute captures more of the proceeds than OWS. The only scenario in which Resolute funding provides a net benefit to OWS is the zero-recovery scenario — the least desirable litigation outcome and, based on the strength of the infringement case, one that we believe is unlikely.
2.  Capacity. OWS and Vantage Point have ample capacity to self-fund the $4.2 million litigation budget. The budget represents approximately 2.2% of OWS's annual revenue and approximately 0.2% of Vantage Point Fund IV's committed capital. Both OWS management and the Vantage Point board representatives have confirmed their willingness to support the litigation budget from existing resources. There is no financial necessity for third-party funding.
3.  Control. Resolute's approval rights over settlement, counsel selection, and significant strategy decisions are inconsistent with OWS's and Vantage Point's strongly expressed desire for unfettered litigation control. The settlement approval threshold of $15 million is particularly concerning because it could prevent OWS from accepting a rational settlement in the event of adverse litigation developments.
4.  Privilege Risk. The unsettled state of the law regarding the application of the common interest doctrine to litigation funder communications, particularly in the Ninth Circuit, creates a meaningful and potentially outcome-determinative risk of privilege waiver. If Lumos's counsel, Victoria Ashworth of Brannick Howell & Stein LLP, were to successfully compel discovery of funder communications, the resulting disclosure could materially damage OWS's litigation position.
5.  signaling. The involvement of a third-party funder may be perceived by Lumos and its advisors as a sign of OWS's financial constraints, potentially emboldening the defense and encouraging a war-of-attrition litigation strategy. Self-funding by a well-capitalized, PE-backed company sends a far stronger signal of commitment and resolve.
Recommended Next Steps. I recommend the following actions:
(a) Alan Ngo should inform Resolute Litigation Finance, LP of OWS's decision to decline the term sheet. The response should be brief, courteous, and non-committal — thanking Resolute for its interest, declining the proposal without extensive explanation, and preserving the relationship for potential consideration in future matters where the economics and circumstances might differ.
(b) This analysis should be presented to the OWS Board of Directors at the May 25, 2022 litigation strategy presentation. The Board should be informed of the Resolute approach, the terms of the term sheet, the financial comparison, and the basis for the recommendation to decline. The self-funding decision should be memorialized in the Board minutes.
(c) Calderwood & Harkness should proceed with final preparation of the complaint for filing in the Northern District of California, consistent with the litigation timeline previously discussed with OWS's General Counsel, Margaret Liu.
I am available to discuss this memorandum and its recommendations at your convenience.
VIII. ENCLOSURES AND ATTACHMENTS
The following materials are enclosed with this memorandum for reference:
Attachment A: Resolute Litigation Finance, LP — Term Sheet (dated approximately May 10, 2022). The complete term sheet as received by Calderwood & Harkness, consisting of twelve pages plus exhibits. This attachment is subject to the confidentiality provisions set forth in the cover letter accompanying the term sheet.
Attachment B: Financial Scenario Analysis — Self-Funding vs. Resolute Funding (Summary Table). A detailed spreadsheet setting forth the four recovery scenarios modeled in Section V.A of this memorandum, including supporting calculations for the waterfall distributions, effective tax rates, and implied returns to Resolute under each scenario.
Attachment C: Clearpath IP Valuation Services, Inc. — Patent Portfolio Valuation Summary (for reference re: expected litigation value). An executive summary of the Clearpath valuation report, including the portfolio-level valuation of $215 million and the individual valuations of the four asserted patents totaling $42.8 million. The full Clearpath report is maintained in the master case file and is available upon request.
PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum, including all attachments, is protected by the attorney-client privilege and the work product doctrine. It has been prepared by counsel in anticipation of litigation and for the purpose of providing legal advice. Any unauthorized disclosure, copying, or distribution is strictly prohibited.
Timekeeper | Role | Standard Rate | Effective Rate (10% discount)
Alan Ngo | Responsible Partner | $1,150/hr | $1,035/hr
Marcus Delgado | Billing Partner | $1,050/hr | $945/hr
Farrah Siddiqui | Senior Associate | $785/hr | $706.50/hr
Thomas Bauer | Associate | $625/hr | $562.50/hr
Scenario | Recovery | Net to OWS (Self-Funded) | Net to OWS (Resolute-Funded) | Cost of Resolute Funding | Effective Tax on Recovery
1: Successful Outcome | $75.0M | $70.8M | $52.08M | $18.72M | 24.96%
2: Moderate Settlement | $25.0M | $20.8M | $9.58M | $11.22M | 44.88%
3: Small Settlement | $10.0M | $5.8M | ~$0 | ~$5.8M | ~58.0%
4: Zero Recovery | $0 | ($4.2M) | ($1.2M) | ($3.0M savings) | N/A

INTERNAL MEMORANDUM

CALDERWOOD & HARKNESS LLP

I. EXECUTIVE SUMMARY

II. BACKGROUND

V. ANALYSIS: SELF-FUNDING VS. RESOLUTE FUNDING

VI. ALTERNATIVE CONSIDERATIONS

VII. RECOMMENDATION

VIII. ENCLOSURES AND ATTACHMENTS

Record

Parties

Dates

Amounts